An Evaluation of the Utility of Big Data to Supplement Cancer Treatment Information: Linkage Between IQVIA Pharmacy Database and the Surveillance, Epidemiology, and End Results Program

Quyen Tran, Joan L. Warren, Michael J. Barrett, Dave Annett, Melissa Marth, Rosemary D. Cress, Dennis Deapen, Sally L. Glaser, Scarlett L. Gomez, Stephen M. Schwartz, Christopher I. Li, Xiao Cheng Wu, Lindsey Enewold, Linda C. Harlan, Donna R. Rivera, Deborah M. Winn, Lynne Penberthy, Kathleen A. Cronin

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Oral anticancer medications (OAMs) are increasingly utilized. We evaluated the representativeness and completeness of IQVIA, a large aggregator of pharmacy data, for breast cancer, colon cancer, chronic myeloid leukemia, and myeloma cases diagnosed in six Surveillance, Epidemiology, and End Results Program (SEER) registries between 2007 and 2011. Patient's SEER and SEER-Medicare data were linked and compared with IQVIA pharmacy data from 2006 to 2012 for specific OAMs. Overall, 67.6% of SEER cases had a pharmacy claim in IQVIA during the treatment assessment window. This varied by location, race and ethnicity, and insurance status. IQVIA consistently identified fewer cases who received an OAM of interest than SEER-Medicare. The difference was least pronounced for breast cancer agents and most pronounced for myeloma agents. The IQVIA pharmacy database included a large portion of persons in the SEER areas. Future studies should assess receipt of OAMs for other cancer sites and in different SEER registries.

Original languageEnglish (US)
Pages (from-to)72-81
Number of pages10
JournalJournal of the National Cancer Institute. Monographs
Volume2020
Issue number55
DOIs
StatePublished - May 1 2020
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'An Evaluation of the Utility of Big Data to Supplement Cancer Treatment Information: Linkage Between IQVIA Pharmacy Database and the Surveillance, Epidemiology, and End Results Program'. Together they form a unique fingerprint.

  • Cite this

    Tran, Q., Warren, J. L., Barrett, M. J., Annett, D., Marth, M., Cress, R. D., Deapen, D., Glaser, S. L., Gomez, S. L., Schwartz, S. M., Li, C. I., Wu, X. C., Enewold, L., Harlan, L. C., Rivera, D. R., Winn, D. M., Penberthy, L., & Cronin, K. A. (2020). An Evaluation of the Utility of Big Data to Supplement Cancer Treatment Information: Linkage Between IQVIA Pharmacy Database and the Surveillance, Epidemiology, and End Results Program. Journal of the National Cancer Institute. Monographs, 2020(55), 72-81. https://doi.org/10.1093/jncimonographs/lgz036